(1) Demonstrated the possibility of delivering an active compound across the BBB using g7-NPs injected in a mouse model for AD(2) these K-NPs have equal or increased activity compared to the free peptide, possibly due to increased peptide stability. Thus, these K-NPs possess full therapeutic potential and overcome the limitations for brain-targeted delivery of the free peptide.
